ContraVir Pharmaceuticals

97 articles about ContraVir Pharmaceuticals

• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.

  10/3/2018

  ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today the appointment of Robert Foster, Pharm.D., Ph.D. as its acting Chief Executive Officer, effectively immediately.

• ContraVir Pharmaceuticals to Present at Virtual Investor Conference

  7/5/2018

  Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A

• ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway

  2/12/2018

  On January 8, 2018, the ContraVir Executive Team met with the FDA’s Division of Antiviral Products at the Center for Drug Evaluation and Research, to review and discuss the data generated for TXL.

• ContraVir Pharmaceuticals Completes Renal Impairment Study With TXL

  2/6/2018

  The study of 16 subjects included 8 healthy subjects with normal kidney function and 8 subjects with severely impaired kidney function.

• ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Determination

  2/5/2018

  The company is taking definitive steps to satisfy the terms of the Panel's decision.

• ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until December 21, 2017

  12/14/2017

  The record date for the Annual Meeting remains October 27, 2017. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

• ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program

  11/6/2017

  As a result, the company expects to receive approximately $1.6 million of net cash proceeds prior to the end of 2017.

• ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431

  10/24/2017

  ContraVir will utilize preclinical services from the NIAID to characterize the antiviral activity of CRV431 in a humanized mouse model of hepatitis B virus infection.

• ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial With TXL

  10/19/2017

• ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology

  10/17/2017

  The collaboration is aimed towards reaching a cure for the Hepatitis B Virus Infection.

• ContraVir Receives HBV IND Approval For Tenofovir Exalidex (TXL) In The United States

  9/11/2017

• ContraVir Announces Acceptance Of Clinical Trial Application In The United Kingdom

  9/6/2017

• ContraVir Announces Issuance Of New U.S. Patent For Expansion Of Cyclophilin Inhibitor Program

  8/21/2017

• ContraVir To Advance Second-Generation Formulation Of Tenofovir Exalidex (TXL) For Treatment Of Hepatitis B Virus (HBV)

  5/4/2017

• ContraVir Announces Pricing Of Public Offering Of Common Stock And Warrants

  4/25/2017

• Data Enhances Understanding Of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) And CRV431

  4/24/2017

• Oral Presentation At EASL Highlights ContraVir’s Tenofovir Exalidex (TXL) Antiviral Activity In Hepatitis B (HBV) Patients

  4/20/2017

• ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)

  4/4/2017

• ContraVir Awarded Grant From Canada's National Research Council To Advance CRV431 For The Treatment Of Hepatitis B

  1/3/2017